Investing.com - Aytu BioScience (NASDAQ:AYTU) reported on Monday first quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Aytu BioScience announced earnings per share of $-0.060 on revenue of $27.66M. Analysts polled by Investing.com anticipated EPS of $-0.240 on revenue of $24.8M.
Aytu BioScience shares are down 85% from the beginning of the year, still down 92.05% from its 52 week high of $2.54 set on November 15, 2021.
Aytu BioScience shares gained 8.91% in after-hours trade following the report.
Aytu BioScience follows other major Healthcare sector earnings this month
Aytu BioScience's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar